Retinal vein occlusion: A form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors

被引:190
作者
Janssen, MCH
den Heijer, M
Cruysberg, JRM
Wollersheim, H
Bredie, SJH
机构
[1] Radboud Univ Nijmegen, Ctr Med, Dept Gen Internal Med 591, NL-6500 HB Nijmegen, Netherlands
[2] Radboud Univ Nijmegen, Ctr Med, Dept Endocrinol & Epidemiol & Biostat, NL-6500 HB Nijmegen, Netherlands
[3] Radboud Univ Nijmegen, Ctr Med, Dept Ophthamol, NL-6500 HB Nijmegen, Netherlands
[4] Radboud Univ Nijmegen, Ctr Med, Ctr Qual Care Res, NL-6500 HB Nijmegen, Netherlands
关键词
retinal vein thrombosis; retinal vein occlusion; risk factors; hyperhomocysteinemia; anticardiolipin antibodies;
D O I
10.1160/TH04-11-0768
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Previous studies have shown an increased risk of retinal vein occlusion (RVO) in patients with hypertension, hypercholesterolemia and diabetes mellitus. Literature on the association between thrombophilic factors and RVO consists of small studies and case reports. The objective was to determine the relationship between thrombophilic risk factors and RVO. Thrombophilic risk factors analyzed were hyperhomocysteinemia, MTHFR gene mutation, factor V Leiden mutation, protein C and S deficiency, antithrombin deficiency, prothrombin gene mutation, anticardiolipin antibodies and lupus anticoagulant. For all currently known thrombophilic risk factors odds ratios for RVO were calculated as estimates of relative risk. The odds ratios were 8.9 (95 % Cl 5.7 -13.7) for hyperhomocysteinemia, 3.9 (95 % Cl 2.3 - 6.7) for anticardiolipin antibodies, 1.2 (95 % Cl 0.9 - 1.6) for MTHFR, 1.5 (95 % Cl 1.0 - 2.2) for factorV Leiden mutation and 1.6 (95 % Cl 0.8 - 3.2) for prothrombin gene mutation. In conclusion, regarding thrombophilic risk factors and RVO there is only evidence for an association with hyperhomocysteinemia and anticardiolipin antibodies, factors that are known as risk factors for venous thrombosis as well as for arterial vascular disease. The minor effect of factorV Leiden mutation and the protrombin gene mutation (risk factors for venous thrombosis only) suggests that atherosclerosis might be an important factor in the development of CRVO.
引用
收藏
页码:1021 / 1026
页数:6
相关论文
共 55 条
[1]   Hyperhomocysteinemia and retinal vascular occlusive disease [J].
Abu El-Asrar, AM ;
Gader, AGMA ;
Al-Amro, SA ;
Al-Attas, OS .
EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2002, 12 (06) :495-500
[2]   Central retinal vein occlusion and thrombophilia risk factors [J].
Adamczuk, YP ;
Varela, MLI ;
Martinuzzo, ME ;
Cerrato, GS ;
Forastiero, RR .
BLOOD COAGULATION & FIBRINOLYSIS, 2002, 13 (07) :623-626
[3]   Retinal vein occlusion and factor V Leiden and prothrombin 20210 G:A mutations [J].
Aras, S ;
Yilmaz, G ;
Alpas, I ;
Baltaci, V ;
Tayanç, E ;
Aydin, P .
EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2001, 11 (04) :351-355
[4]   Clinical characteristics of retinal venous occlusions occurring at different sites [J].
Beaumont, PE ;
Kang, HK .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2002, 86 (05) :572-580
[5]   Prevalence of hereditary thrombophilia in patients with thrombosis in different venous systems [J].
Bombeli, T ;
Basic, A ;
Fehr, J .
AMERICAN JOURNAL OF HEMATOLOGY, 2002, 70 (02) :126-132
[6]   Plasma homocysteine, methylene tetrahydrofolate reductase C677T and factor II G20210A polymorphisms, factor VIII, and VWF in central retinal vein occlusion [J].
Boyd, S ;
Owens, D ;
Gin, T ;
Bunce, K ;
Sherafat, H ;
Perry, D ;
Hykin, PG .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2001, 85 (11) :1313-1315
[7]   Homocysteine: A risk factor for retinal venous occlusive disease [J].
Brown, BA ;
Marx, JL ;
Ward, TP ;
Hollifield, RD ;
Dick, JS ;
Brozetti, JJ ;
Howard, RS ;
Thach, AB .
OPHTHALMOLOGY, 2002, 109 (02) :287-290
[8]   Raised plasma homocysteine as a risk factor for retinal vascular occlusive disease [J].
Cahill, M ;
Karabatzaki, M ;
Meleady, R ;
Refsum, H ;
Ueland, P ;
Shields, D ;
Mooney, D ;
Graham, I .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2000, 84 (02) :154-157
[9]   Thermolabile MTHFR genotype and retinal vascular occlusive disease [J].
Cahill, M ;
Karabatzaki, M ;
Donoghue, C ;
Meleady, R ;
Mynett-Johnson, LA ;
Mooney, D ;
Graham, IM ;
Whitehead, AS ;
Shields, DC .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2001, 85 (01) :88-90
[10]  
Carbone J, 2001, J RHEUMATOL, V28, P2437